Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target

JOURNAL ARTICLE published November 2018 in Cancer Letters

Research funded by Bio and Medical Technology Development Program (2012M3A9B6055305) | Multiomics Research Program (NRF-2012M3AB9036675) | National Institutes of Health grants (1U01DK103260,1R01DK100974,U24 DK097154,NIH NCATS UCLA CTSI UL1TR000124) | Department of Defense (W81XWH-15-1-0415) | Centers for Disease Controls and Prevention (1U01DP006079)

Authors: Jae Hun Jung | Sungyong You | Jae Won Oh | Junhee Yoon | Austin Yeon | Muhammad Shahid | Eunho Cho | Vikram Sairam | Taeeun D. Park | Kwang Pyo Kim | Jayoung Kim